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Abstract: Pharmacokinetics of cefepime was determined following single dose intravenous (IV) and intramuscular (IM)
administration at the rate of 10 mg/kg body weight in a crossover design with an interval of 21 days between IV and IM injections.
The experiment was done on 6 healthy young female Surati goats (4-6 months of age). All animals were randomly allocated to
receive either IV or IM injection of the drug. Blood samples were collected at various time intervals. Cefepime concentration in serum
was determined by high performance liquid chromatography (HPLC). The serum drug concentration-time profile was characteristic
of a 2- and 1-compartment open model following IV and IM administration, respectively. Following single dose IV administration,
the drug was rapidly distributed (t1/2α: 0.20 ± 0.02 h; Vd (area); 0.52 ± 0.04 l/kg) and slowly eliminated (t1/2β: 2.71 ± 0.08 h) from
the body. Following IM administration, the drug was rapidly absorbed (t1/2ka: 0.16 ± 0.01 h) and slowly eliminated (t1/2β: 4.89 ±
0.24 h) from body. The bioavailability of cefepime was 69 ± 6.0% following IM injection. Based on observed serum drug
concentration, cefepime can be used intramuscularly at the dose rate of 10 mg/kg every 12 h in goats.
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Introduction
Cefepime is a semisynthetic, parenteral fourthgeneration cephalosporin antibiotic. It is stable to
hydrolysis by common plasmid and chromosomally
mediated β-lactamases. Cefepime shows broad spectrum
of activity, which includes Gram-positive cocci, enteric
Gram-negative bacilli, and Pseudomonas aeruginosa. It
lacks activity against methicillin-resistant Staphylococcus
aureus, enterococci, Bacteroides fragilis, and Listeria
monocytogenes (1,2). It was found highly active against
canine isolates of Staphylococcus intermedius,
Pseudomonas aeruginosa, and Escherichia coli (3).
Diseases like coliform septicaemia, pneumonia,
colibacillosis, and meningitis are major causes of neonatal
mortality in sheep and goats where cefepime may be
highly effective in treating bacterial infections.
Pharmacokinetics of cefepime has been determined
for rats and monkey (4), men (5), foals and dogs (6),
horses (7), calves (8), and ewes (9). Despite the great

potential for clinical use of cefepime in veterinary
medicine, the data on its pharmacokinetics in goats are
limited. The present study was therefore planned to
determine various pharmacokinetic parameters of
cefepime following IV and IM injection in goats.

Material and Methods
Experimental Animals
The experiment was conducted on 6 healthy young
(4-6 months of age) Surati female goats (Capra hircus
L.), weighing 25-34 kg. The work was carried at the
instructional farm of the College of Veterinary Science
and Animal Husbandry, Anand Agricultural University,
Anand (India). The experimental protocol was approved
by the institutional animal ethics committee. The animals
were examined clinically to establish health status and to
rule out the possibility of any diseases. Each animal was
housed in a separate pen and provided standard ration.
Water was provided ad libitum.

* E-mail: skbhavsar@aau.in

159

Single Dose Pharmacokinetics of Cefepime after Intravenous and Intramuscular Administration in Goats

Drugs and Chemicals
Pure cefepime standard powder was obtained from
Aurobindo Pharma Ltd., Hyderabad, India. Cefepime
hydrochloride (1.19 g) (Novapime, Lupin Ltd., Mumbai,
India) equivalent to cefepime 1 g for injection was
purchased from market. Sodium acetate, acetic acid,
water, acetonitrile, methanol, and perchloric acid (70%)
of HPLC grade were procured from Merck India Ltd.,
Mumbai.
Experimental Design
Study was conducted in a cross over design with an
interval of 21 days between 2 successive injections. All
goats were randomly allocated to receive either IV or IM
injection. Cefepime hydrochloride (Novapime, Lupin Ltd,
Mumbai, India) was diluted with sterile water to make
concentration of 100 mg/ml and administered at a rate of
10 mg/kg body weight. IV injection of the drug was given
in the left jugular vein, while IM injection was given in the
gluteal muscles, using a 20 G × 25 mm sterile needle.
Blood samples (3-4 ml) were collected from IV
catheter (Mediflon, 22 × 0.9 × 25 mm) fixed into the
right jugular vein. The blood samples were drawn into
clean sterilized test tubes. Blood samples were collected
at 0 time (before drug administration), and at 0.033 (2
min), 0.083 (5 min), 0.166 (10 min), 0.25 (15 min), 0.5
(30 min), 1, 2, 4, 6, 8, 12, 18, and 24 h after IV
administration. Following IM administration, the blood
samples were collected at 0 time (before drug
administration), and at 0.083 (5 min), 0.166 (10 min),
0.25 (15 min), 0.5 (30 min), 1, 2, 4, 6, 8, 12, 18, 24,
and 36 h. The blood samples were allowed to clot and
serum was harvested from all samples by centrifugation
at 4192.5 g for 15 min. The serum samples were then
stored at – 40 °C and analyzed within 24 h.
Cefepime HPLC Assay
Cefepime concentration in serum samples was
determined by reverse-phase high performance liquid
chromatography (HPLC) after extraction, using a
reported assay with some modifications (6). The HPLC
system (Knauer, Germany) comprised of isocratic solvent
delivery pump (model K 501) and UV detector (model K
2501). Chromatographic separations were performed
using reverse phase C18 column (Zorbax, ODS; 25 cm ×
46 mm ID) at room temperature. The data integration
was performed using Eurochrome software (Version
2000). The mobile phase was a mixture of 0.2 M sodium
160

acetate (3.2%), 0.2 M acetic acid (2.2%), acetonitrile
(10.0%), and HPLC water (84.6%) having pH 5.1.
Mobile phase was filtered by a 0.45 µ filter and pumped
into column at a flow rate of 1.5 ml/min at ambient
temperature. The effluent was monitored at 257 nm
wavelength.
Serum samples were deproteinized by diluting 500 µl
of serum with 500 µl of 0.8 M perchloric acid and
centrifuged at 4192.5 g for 10 min. The clean
supernatant was collected and an aliquot of 20 µl of this
supernatant was injected into the loop of HPLC system
through manual injector. Calibration curve was prepared
by adding known amount of cefepime to blank unfortified
serum for the expected range of concentrations from 0.1
to 100 µg/ml. Quantification was done by reference to
the resultant calibration curve. The calibration curve was
prepared daily and not accepted unless it had a R2 value
> 0.99. The lower limit of quantitation (LLOQ) was 0.5
µg/ml. The assay was sensitive and reproducible, and
linearity was observed from 0.5 to 100 µg/ml with a
mean correlation coefficient of 0.9985. Precision and
accuracy were determined with quality control (QC)
samples at concentrations of 0.5, 10, and 100 µg/ml (5
replicates, each, per day). The intraday and interday
coefficients of variation for 5 QC samples were
satisfactory, with relative standard deviations (RSD) less
than 8.55%. Intraday and interday variations were under
acceptable limits. The retention time of cefepime was 5.0
min.
Data Analysis
The intravenous serum drug concentration versus
time data plot followed 2-compartment open model,
whereas intramuscular disposition followed 1compartment open model. Serum drug concentrations
versus time data were best fitted to compartment models
using Pharmkit software (Version 2.0). Pharmacokinetic
parameters were calculated using the following formulas
(10-12):
t1/2 β = 0.693
β
AUC (0 - ∝) and AUMC were calculated by Trapezoidal
rule.
Vd(area) =

Dose (For Intravenous Injection)
β × AUC

Vd(area) = Dose × F (For Intramuscular Injection)
β × AUC
Vd(ss) = Dose × AUMC
(AUC)2
ClB = β × Vd(area) × 1000
MRT = AUMC
AUC
F = Dose (I.V.) x AUC (I.M.) x 100
Dose (I.M.) x AUC (I.V.)

Serum Cefepime Concentration (µg/ml)
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Comparative disposition of cefepime following single
dose IV and IM administration in goats is shown in the
Figure as a semilogarithmic plot. Pharmacokinetic
parameters are presented in the Table. Following single
dose IV administration, distribution half-life, elimination
half-life, apparent volume of distribution, area under
serum drug concentration-time curve, and total body
clearance were 0.20 ± 0.02 h, 2.71 ± 0.08 h, 0.52 ±
-1
0.04 l/kg, 78.38 ± 7.05 µg. h ml and 2.19 ± 0.15
ml/min/kg, respectively. Following IM administration,
peak serum drug concentration, elimination half-life, area

6

8

10

12

14

16

18

Time (h)

(For Intramuscular Injection)

Results

4

Semilogarithmic plot of serum cefepime concentrations
versus time following single dose IV and IM administrations
at the rate of 10 mg/kg of body weight in goats. Each point
represents the Mean ± S.E. of 6 animals.

under the serum concentration-time curve, total body
clearance, and systemic bioavailability were 15.75 ± 2.39
-1
µg/ml, 4.89 ± 0.24 h, 93.12 ± 10.14 µg. h ml , 1.27 ±
0.08 ml/min/kg, and 69 ± 6.0%, respectively.

Discussion
Following IV and IM administration, cefepime serum
concentration verses time data can be best fitted to a 2compartment and a 1-compartment open model,

Table. Pharmacokinetic parameters of cefepime in goats after single dose IV and IM administration (10 mg/kg of body weight).
Pharmacokinetic
Parameters
t1/2α
t1/2β
t1/2k(a)
AUC (0 - ∞)
AUMC
Vd (area)
Vd (ss)
K12 / K21
Cl (B)
MRT
F
Cmax
Tmax

Unit

IV
(Mean ± S.E., n = 6)

IM
(Mean ± S.E., n = 6)

h
h
h
µg. h/ml
µg. h2/ml
L/kg
L/kg
ratio
ml/min/kg
h
%
µg/ml
h

0.20 ± 0.02
2.71 ± 0.08
78.38 ± 7.05
203.80 ± 10.05
0.52 ± 0.04
0.35 ± 0.03
2.34 ± 0.33
2.19 ± 0.15
2.64 ± 0.09
-

4.89 ± 0.24
0.16 ± 0.01
93.12 ± 10.14
492.30 ± 49.52
1.27 ± 0.08
4.89 ± 0.57
69 ± 6
15.75 ± 2.39
0.50

t1/2α: half-life of distribution phases; t1/2β: elimination half life; t1/2k(a): absorption half-life; AUC(0 - ∞): total area under plasma drug concentration-time
curve; AUMC: area under first of moment curve; Vd (area): volume of distribution based on area; Vd (ss): volume of distribution at steady state; K12: rate
of transfer of drug from central to peripheral compartment; K21: rate of transfer of drug from peripheral to central compartment; Cl (B): total body
clearance; MRT: mean residence time; F: bioavailability; Cmax: maximum drug concentration; Tmax: time of maximum concentration observed in serum.
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respectively, which was supported by disposition
characteristics of cefepime reported in men (5) and
animals (6-8). The elimination half-life (2.71 ± 0.08 h)
determined in the present study is longer than that
reported in ewes (1.76 ± 0.07 h) (9) but shorter than
that determined in foals (1.65 ± 0.10 h) and dogs (1.09
± 0.27 h) (6). Clearance of cefepime observed in the
present study is in agreement with that reported in ewes
(9). In contrast, slower clearance of the drug has been
reported in horses (6,7) and calves (8). The drug is
widely distributed in the body as determined by apparent
volume of distribution observed in the present study. This
is in line with that reported in ewes (9). Higher ratio of
K12 / K21 observed in the present study also suggests
faster and wider distribution of drug into the tissues of
goats.

Following IM administration, peak serum cefepime
concentration (21.10 ± 1.85 µg/ml) was achieved at 1 h
(tmax), which is lower than the peak cefepime
concentration (31.9 ± 1.5 µg/ml) observed in ewes (9).
The peak serum cefepime concentration observed in
calves (8) is in line with that observed in goats.
Elimination half-life following IM injection of the drug in
the present study is longer than that reported in goats (9)
and calves (8). The systemic bioavailability of cefepime
following IM injection is less than that reported in ewes
(86.8 ± 7.5%) (9) and calves (95.7 ± 7.44%) (8). Based
on the observed serum drug concentration following IM
administration of the drug in the present study,
therapeutic concentration is maintained for up to 12 h,
therefore IM injection of cefepime at the rate of 10
mg/kg may be used as a therapeutic dose in goats.
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